[1] ADEGHATE E， KALASZ H， VERESS G， et al. Medicinal chemistry of drugs used in diabetic cardiomyopathy [J]. Curr Med Chem， 2010， 17(6)： 517-551.
[2] SOLOMON S D， SKALI H， ANAVEKAR N S， et al. Changes in ventricular size and function in patients treated with valsartan， captopril， or both after myocardial infarction [J]. Circulation， 2005， 111(25)： 3411-3419.
[3] FERREIRA A J， JACOBY B A， ARAUJO C A， et al. The nonpeptide angiotensin-(1-7) receptor Mas agonist AVE-0991 attenuates heart failure induced by myocardial infarction [J]. Am J Physiol Heart Circ Physiol， 2007， 292(2)： 1113-1119.
[4] QI F， WANG X M， YANG L X， et al. Effects of angiotensin(1-7) on cell proliferation and collagen synthesis of cardiac fibroblasts induced by angiotensin Ⅱ [J]. Chin J Arterioscler（中国动脉硬化杂志）， 2007， 15(05)： 361-364.
[5] TALLANT E A， FERRARIO C M， GALLAGHER P E. Angiotensin-(1-7) inhibits growth of cardiac myocytes through activation of the mas receptor [J]. Am J Physiol Heart Circ Physiol， 2005， 289(4)： 1560-1566.
[6] FERRARIO C M， JESSUP J， CHAPPELL M C， et al. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2 [J]. Circulation， 2005， 111(20)： 2605-2610.
[7] DOUILLETTE A， BIBEAU-POIRIER A， GRAVEL S P， et al. The proinflammatory actions of angiotensin II are dependent on p65 phosphorylation by the IkappaB kinase complex [J]. J Biol Chem， 2006， 281(19)： 13275-13284.
[8] KAWANO S， KUBOTA T， MONDEN Y， et al. Blockade of NF-kappaB improves cardiac function and survival after myocardial infarction [J]. Am J Physiol Heart Circ Physiol， 2006， 291(3)： 1337-1344.
[9] AL-MAGHREBI M， BENTER I F， DIZ D I. Endogenous angiotensin-(1-7) reduces cardiac ischemia-induced dysfunction in diabetic hypertensive rats [J]. Pharmacol Res， 2009， 59(4)： 263-268.
[10] HIGUCHI Y， CHAN T O， BROWN M A， et al. Cardioprotection afforded by NF-kappaB ablation is associated with activation of Akt in mice overexpressing TNF-alpha [J]. Am J Physiol Heart Circ Physiol， 2006， 290(2)： 590-598.
[11] PENG H， CARRETERO O A， LIAO T D， et al. Role of N-acetyl-seryl-aspartyl-lysyl-proline in the antifibrotic and anti-inflammatory effects of the angiotensin-converting enzyme inhibitor captopril in hypertension [J]. Hypertension， 2007， 49(3)： 695-703.
[12] RUIZ-ORTEGA M， RODRIGUEZ-VITA J， SANCHEZ-LOPEZ E， et al. TGF-beta signaling in vascular fibrosis [J]. Cardiovasc Res， 2007， 74(2)： 196-206.
[13] CASTOLDI G， DI GIOIA C R， BOMBARDI C， et al. Prevention of myocardial fibrosis by N-acetyl-seryl-aspartyl-lysyl-proline in diabetic rats [J]. Clin Sci (Lond)， 2009， 118(3)： 211-220.
[14] YAO H M， XIONG S X， SONG C F. To Investigate the protection of captopril and ramipril on the interstitium of diabetic cardiomyopathy [J]. J Mathemat Med（数理医药学杂志）， 2009， 22(2)： 174-176.
[15] SINGH V P， LE B， KHODE R， et al. Intracellular angiotensin II production in diabetic rats is correlated with cardiomyocyte apoptosis， oxidative stress， and cardiac fibrosis [J]. Diabetes， 2008， 57(12)： 3297-3306.
[16] CHRYSANT G S， NGUYEN P K. Moexipril and left ventricular hypertrophy [J]. Vasc Health Risk Manag， 2007， 3(1)： 23-30.
[17] NICOLOSI G L， GOLCEA S， CECONI C， et al. Effects of perindopril on cardiac remodelling and prognostic value of pre-discharge quantitative echocardiographic parameters in elderly patients after acute myocardial infarction： the PREAMI echo substudy [J]. Eur Heart J， 2009， 30(19)： 2327-2336.
[18] WOLKART G， PANG X， STESSEL H， et al. Chronic endothelin-A receptor antagonism is as protective as angiotensin converting enzyme inhibition against cardiac dysfunction in diabetic rats [J]. Br J Pharmacol， 2007， 151(8)： 1187-1197.
[19] SYMEONIDES P， KOULOURIS S， VRATSISTA E， et al. Both ramipril and telmisartan reverse indices of early diabetic cardiomyopathy： a comparative study [J]. Eur J Echocardiogr， 2007， 8(6)： 480-486.
[20] CAO J L， XIONG S X， SONG C F， et al. Comparison between fosinopril and imidapril in protection of myocardium of diabetic rats [J]. Chin Heart J（心脏杂志）， 2009， 21(04)： 480-483.
[21] AROZAL W， WATANABE K， VEERAVEEDU P T， et al. Effects of angiotensin receptor blocker on oxidative stress and cardio-renal function in streptozotocin-induced diabetic rats [J]. Biol Pharm Bull， 2009， 32(8)： 1411-1416.
[22] ZHANG C H， LU J， YU X J， et al. Ameliorative effect of Captopril and Valsartan on an animal model of diabetic cardiomyopathy [J]. Biol Pharm Bull， 2008， 31(11)： 2045-2049.
[23] VAN LINTHOUT S， SEELAND U， RIAD A， et al. Reduced MMP-2 activity contributes to cardiac fibrosis in experimental diabetic cardiomyopathy [J]. Basic Res Cardiol， 2008， 103(4)： 319-327.
[24] WESTERMANN D， RUTSCHOW S， JAGER S， et al. Contributions of inflammation and cardiac matrix metalloproteinase activity to cardiac failure in diabetic cardiomyopathy： the role of angiotensin type 1 receptor antagonism [J]. Diabetes， 2007， 56(3)： 641-646.
[25] WANG X H， YIN S L， ZHAO Y P， et al. Effects of telmisartan on the expression of hepatocyte growth factor in myocardium of rats with diabetes mellitus [J]. Hebei Med J（河北医学）， 2009， 31(18)： 2367-2369.
[26] TANG M X ， GUO Y， ZHOU Y L， et al. Experimental study on heart function protective effects of telmisartan on diabetic cardiomyopathy in rats [J]. J Clin Res， 2009， 26(5)： 845-847.
[27] FU L J， WANG H X， LIU W Z. Effects of candesartan on apoptosis and expressions of Fas and Fas-L in the myocardium cell of diabetic rats [J]. Chin Pharmacol Bull（中国药理学通报）， 2009， 25(10)： 1394-1395.
[28] YARAS N， BILGINOGLU A， VASSORT G， et al. Restoration of diabetes-induced abnormal local Ca2+ release in cardiomyocytes by angiotensin II receptor blockade [J]. Am J Physiol Heart Circ Physiol， 2007， 292(2)： 912-920.
[29] KAWASAKI D， KOSUGI K， WAKI H， et al. Role of activated renin-angiotensin system in myocardial fibrosis and left ventricular diastolic dysfunction in diabetic patients--reversal by chronic angiotensin II type 1A receptor blockade [J]. Circ J， 2007， 71(4)： 524-529.
[30] ITOH S， DING B， SHISHIDO T， et al. Role of p90 ribosomal S6 kinase-mediated prorenin-converting enzyme in ischemic and diabetic myocardium [J]. Circulation， 2006， 113(14)： 1787-1798.